F-3

Chunghwa Telecom Reports 2024 Guidance

Retrieved on: 
Friday, January 26, 2024
PP, Income tax, Bank statement, Forecasting, International Financial Reporting Standards, Asset, Chunghwa Telecom, International, Prospectus, Sale, Note 2, PP&E, F-3, Depreciation, Financial Supervisory Commission, Bank

Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.

Key Points: 
  • Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.
  • In addition to the consolidated financial results prepared under T-IFRSs, Chunghwa Telecom also provide non-GAAP financial measures, including "EBITDA".
  • Further, these non-GAAP financial measures may be unique to Chunghwa Telecom, as they may be different from non-GAAP financial measures used by other companies.
  • As such, this presentation of non-GAAP financial measures may not enhance the comparability of the Company's results to the results of other companies.

Foresight Autonomous Holdings Ltd. Announces Pricing of $4.5 Million Registered Direct Offering

Retrieved on: 
Thursday, December 7, 2023
Telephone, ADS, Sale, Prospectus, Madison Avenue, F-3, Security (finance)

The gross proceeds of the offering will be approximately $4.5 million, before deducting placement agent fees and other estimated offering expenses.

Key Points: 
  • The gross proceeds of the offering will be approximately $4.5 million, before deducting placement agent fees and other estimated offering expenses.
  • The closing of the offering is expected to occur on or about December 11, 2023, subject to the satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds of this offering for working capital and other general corporate purposes.
  • A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

Atour Lifestyle Holdings Limited Announces Pricing of Upsized Registered Secondary Offering of American Depositary Shares by Legend Capital

Retrieved on: 
Wednesday, December 6, 2023
Telephone, ADS, Sale, Content management system, Garden Road, Form, Legend Holdings, CMBI, Attention, BofA Securities, ATAT, Prospectus, Broadridge Financial Solutions, Capital, Bryant Park, F-3, Exercise, Security (finance)

SHANGHAI, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Atour Lifestyle Holdings Limited (“Atour” or the “Company”) (NASDAQ: ATAT), a leading hospitality and lifestyle company in China, today announced the pricing of an upsized registered secondary underwritten offering by entities affiliated with Legend Capital (“Legend Capital”) of an aggregate of 9,600,000 American depositary shares (the “ADSs” and such offering, the “Secondary Offering”), each ADS representing three Class A ordinary shares of par value US$0.0001 each of the Company, at an offering price of US$15.80 per ADS.

Key Points: 
  • SHANGHAI, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Atour Lifestyle Holdings Limited (“Atour” or the “Company”) (NASDAQ: ATAT), a leading hospitality and lifestyle company in China, today announced the pricing of an upsized registered secondary underwritten offering by entities affiliated with Legend Capital (“Legend Capital”) of an aggregate of 9,600,000 American depositary shares (the “ADSs” and such offering, the “Secondary Offering”), each ADS representing three Class A ordinary shares of par value US$0.0001 each of the Company, at an offering price of US$15.80 per ADS.
  • The Secondary Offering was upsized from 8,000,000 ADSs, as previously disclosed, to 9,600,000 ADSs.
  • The underwriters in the Secondary Offering will have a 30-day option to purchase up to 1,440,000 additional ADSs from Legend Capital.
  • BofA Securities, Inc., CMB International Capital Limited and Citigroup Global Markets Inc. act as the joint bookrunners for the Secondary Offering.

Chunghwa Telecom Reports Un-Audited Consolidated Operating Results for the Third Quarter of 2023

Retrieved on: 
Thursday, November 2, 2023
Internet of things, Chunghwa Telecom, Comparison, Yoy, Sale, ARPU, NYSE, International, Financial Supervisory Commission, TAIEX, EBITDA, Protocol, Quarter, IDC, Electricity, International Financial Reporting Standards, IBG, Bank statement, IPhone, CBG, Growth, F-3, EPS, Prospectus, Income tax, CHT, Financial Supervisory Commission (Taiwan), Depreciation, Forecasting, ICT, SECURE Act, Video game, Telecommunications, Holding company, Mobile phone, Bank

TAIPEI, Nov. 2, 2023 /PRNewswire/ -- Chunghwa Telecom Co., Ltd. (TAIEX: 2412, NYSE: CHT) ("Chunghwa" or "the Company") today reported its un-audited operating results for the third quarter of 2023.

Key Points: 
  • TAIPEI, Nov. 2, 2023 /PRNewswire/ -- Chunghwa Telecom Co., Ltd. (TAIEX: 2412, NYSE: CHT) ("Chunghwa" or "the Company") today reported its un-audited operating results for the third quarter of 2023.
  • "We had another sound quarter with results exhibiting healthy momentum in various parts of our business," said Mr. Shui-Yi, Kuo, Chairman and Chief Executive Officer of Chunghwa Telecom.
  • Chunghwa Telecom's total revenues for the third quarter of 2023 increased by 0.3% to NT$ 53.66 billion.
  • In addition to the consolidated financial results prepared under T-IFRSs, Chunghwa Telecom also provide non-GAAP financial measures, including "EBITDA".

ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution

Retrieved on: 
Wednesday, September 20, 2023
Technology, Clinical Trials, Professional Services, Software, Biotechnology, Health, Data Analytics, Pharmaceutical, Data Management, F-1, ISO, COVID-19, Clinical trial, F-3, Privacy, F-4, Patient, ICLR, S-8, Ecosystem, ICON PLC, Disease, Pharmaceutical industry, Medical imaging, Medical device, ICON

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution.

Key Points: 
  • ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution.
  • ICON’s next generation proprietary Clinical Trial Tokenisation solution seamlessly integrates all the necessary components to allow for the collation of patient data in a consented, discreet and non-intrusive way with Privacy Protected Record Linkage (PPRL) across time and source.
  • ICON’s Clinical Trial Tokenisation solution is delivered within an operating framework aligned to industry security and data privacy standards, and its corporate security and data protection programs have been assessed to ISO 27001 and 27701 standards.
  • Steve Cutler, CEO, ICON commented: “As an early pioneer of clinical trial tokenisation, ICON fully understands the potential it has to transform clinical development.

POET Technologies Reports Second Quarter 2023 Financial Results

Retrieved on: 
Friday, August 11, 2023
Exercise, POET, TSX Venture Exchange, CXL, OSFP, File, Marketing, Die (integrated circuit), F-3, AGM, Research, EDGAR, Sale, PTK, ATM, Zenith Contract Services, Financial statement, TMX Group, Engineering, Infinity, SEDAR, SPX, Form, Average cost, Special, Depreciation, Growth, Programmable interrupt controller, NRE, News, Capital Group Companies, Cryptocurrency, Security (finance), Beauty salon

TORONTO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today reported its consolidated financial results for the second quarter ended June 30, 2023.

Key Points: 
  • TORONTO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today reported its consolidated financial results for the second quarter ended June 30, 2023.
  • The Company had non-cash finance costs of $11,000 in the second quarter of 2023 compared to non-cash finance costs of $13,000 in the second quarter of 2022 and non-cash finance costs of $11,000 in the first quarter of 2023.
  • The Company’s share of loss was approximately 80.7% of the loss of SPX in the second quarter of 2023, 88.5% in the second quarter of 2022 and 80.7% in the first quarter of 2023.
  • Cash flow from operating activities in the second quarter of 2023 was ($4.0) million, compared to ($3.4) million in the second quarter of 2022 and ($4.4) million in the first quarter of 2023.

Chunghwa Telecom Reports Un-Audited Consolidated Operating Results for the Second Quarter of 2023

Retrieved on: 
Tuesday, August 8, 2023
IDC, IPhone, Wi-Fi, International, SECURE Act, CHT, Bank statement, Financial Supervisory Commission (Taiwan), Internet of things, Income tax, F-3, IBG, Forecasting, Sale, ARPU, Chunghwa Telecom, Prospectus, ICT, EBITDA, NTD, Depreciation, Growth, TAIEX, EPS, Yoy, AI, Financial Supervisory Commission, Comparison, NYSE, Total, Video game, Music, Tourism, Drug, Bookkeeping, Cryptocurrency, Mobile phone, Bank

TAIPEI, Aug. 8, 2023 /PRNewswire/ -- Chunghwa Telecom Co., Ltd. (TAIEX: 2412, NYSE: CHT) ("Chunghwa" or "the Company") today reported its un-audited operating results for the second quarter of 2023.

Key Points: 
  • TAIPEI, Aug. 8, 2023 /PRNewswire/ -- Chunghwa Telecom Co., Ltd. (TAIEX: 2412, NYSE: CHT) ("Chunghwa" or "the Company") today reported its un-audited operating results for the second quarter of 2023.
  • Chunghwa Telecom's total revenues for the second quarter of 2023 increased by 2.0% to NT$ 53.46 billion.
  • EBITDA for the second quarter of 2023 was NT$ 22.19 billion, increasing by 1.0% year over year.
  • In addition to the consolidated financial results prepared under T-IFRSs, Chunghwa Telecom also provide non-GAAP financial measures, including "EBITDA".

Quarterly Activities and Cashflow Report

Retrieved on: 
Monday, July 31, 2023
Psychopharmacology, Regulation of tobacco by the U.S. Food and Drug Administration, Employment, Central nervous system, BNC210, Quarter, Post-traumatic stress disorder, Comptroller, Audit, American depositary receipt, Delisting, F-3, Educational Strategy for Developing Societies, BNO, ASX, SAD, Research, Bionomics, CNS, Sale, Development, ATM, Prospectus, Patient, Form, CFO, FDA, Society, Conference, Food, PTSD, Pharmaceutical industry, Security (finance), Cryptocurrency, Management, Online shopping, Cantor

On 28 April 2023, Bionomics released its Appendix 4C – Quarterly Cashflow Report for the quarter ended 31 March 2023.

Key Points: 
  • On 28 April 2023, Bionomics released its Appendix 4C – Quarterly Cashflow Report for the quarter ended 31 March 2023.
  • Bionomics may determine to sell some, all, or none of the ADSs under the ATM Program and may terminate the ATM Program at its discretion.
  • Start-up activities for a planned Phase 3 trial of BNC210 in SAD are underway.
  • A copy of the full release, including a copy of the ASX Appendix 4C Cashflow Report can be found on the Company's website.

ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting

Retrieved on: 
Wednesday, July 26, 2023
Research, Medical Devices, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Government, F-1, COVID-19, S-8, ICON, F-3, F-4, ICON PLC, Medicine

All resolutions are ordinary resolutions unless otherwise stated.

Key Points: 
  • All resolutions are ordinary resolutions unless otherwise stated.
  • These statements are based on management's current expectations and information currently available, including current economic and industry conditions.
  • The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements.
  • With headquarters in Dublin, Ireland, ICON employed approximately 41,160 employees in 108 locations in 53 countries as at June 30, 2023.

ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform

Retrieved on: 
Monday, June 26, 2023
Health, Medical Devices, Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology, F-1, Digital platform (infrastructure), American Opportunity Tax Credit, COVID-19, API, Clinical trial, F-3, F-4, Patient, Translation, ICLR, S-8, Digital, Digital platform, ICON PLC, Medical device, Medical imaging, ICON

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced the latest release of its Digital Platform .

Key Points: 
  • ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced the latest release of its Digital Platform .
  • The ICON Digital Platform is an end-to-end solution that enables patient services throughout clinical trials including an easy-to-use patient mobile app, eConsent, eCOA, direct data capture for in-home services, televisits and digital health technology management.
  • It offers the technical functionality, standard capability and integrated services, in one platform, that enable flexibility for any clinical trial.
  • Steve Cutler, CEO, ICON, commented: “This newest version of the Digital Platform enables the efficient capture and delivery of quality data from a range of decentralised clinical trial services.